No SGLT2i

OTHER2 trials

Sponsors

University of Chicago

Conditions

Acute Decompensated Heart FailureHeart Failure With Reduced Ejection Fraction

Phase 4

HF Patients With LVADs Being Treated With SGLT2i

CompletedNCT05278962

University of ChicagoHeart Failure With Reduced Ejection Fraction

Start: 2022-09-08End: 2025-08-31Updated: 2025-09-09

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

TerminatedNCT05346653

University of ChicagoAcute Decompensated Heart Failure

Start: 2023-05-22End: 2023-05-23Updated: 2024-09-04

Related Papers

Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol

BMJ Open2024-10-011 citations